Literature DB >> 29270596

[Astrocytes as therapeutic targets after spinal cord injury].

Xiao Huang1, Ya-Kun Gu1, Xue-Yan Cheng1, Zhi-Da Su2.   

Abstract

Spinal cord injury (SCI) is a challenging medical problem in the field of neurology, showing high incidence rate, disability rate, treatment cost and low-aged trend. Despite the clinical application of drug intervention, surgical treatment and modern rehabilitation training, no ideal curative effect has been achieved. Therefore, future study is necessary to clarify detailed pathological mechanism of SCI and identify the potential target cells for therapeutic intervention. In the central nervous system (CNS), astrocytes are the most abundant and widely distributed glial cells which play multiple key roles in maintaining homeostasis of the CNS in physiological and pathological conditions. Increasing evidence indicates that astrocytes are ideal therapeutic target cells for SCI. Here, we review current knowledge of the roles of astrocytes in the pathological reaction after SCI, astroglial transplantation and astrocyte reprogramming.

Entities:  

Mesh:

Year:  2017        PMID: 29270596

Source DB:  PubMed          Journal:  Sheng Li Xue Bao        ISSN: 0371-0874


  3 in total

1.  miRNA Therapy in Laboratory Models of Acute Spinal Cord Injury in Rodents: A Meta-analysis.

Authors:  Yang Wang; Hanxiao Yi; Yancheng Song
Journal:  Cell Mol Neurobiol       Date:  2022-06-01       Impact factor: 5.046

2.  MicroRNA-182 improves spinal cord injury in mice by modulating apoptosis and the inflammatory response via IKKβ/NF-κB.

Authors:  Min Fei; Zheng Li; Yuanwu Cao; Chang Jiang; Haodong Lin; Zixian Chen
Journal:  Lab Invest       Date:  2021-05-31       Impact factor: 5.662

Review 3.  Biological Functions and Therapeutic Potential of Autophagy in Spinal Cord Injury.

Authors:  Hai-Yang Liao; Zhi-Qiang Wang; Rui Ran; Kai-Sheng Zhou; Chun-Wei Ma; Hai-Hong Zhang
Journal:  Front Cell Dev Biol       Date:  2021-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.